Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	ATP transmembrane transporter activity	SLC25A24 SLC25A25 SLC25A31	8.69e-05	14	127	3	GO:0005347
GeneOntologyMolecularFunction	ATP:phosphate antiporter activity	SLC25A24 SLC25A25	1.20e-04	3	127	2	GO:0140987
GeneOntologyMolecularFunction	minus-end-directed microtubule motor activity	DYNC2H1 DNAH9 DYNC1H1	1.91e-04	18	127	3	GO:0008569
GeneOntologyMolecularFunction	carnitine O-palmitoyltransferase activity	CPT1A CPT2	2.39e-04	4	127	2	GO:0004095
GeneOntologyMolecularFunction	nuclear estrogen receptor binding	NSD1 NCOR1 LATS1 NCOA1	3.59e-04	53	127	4	GO:0030331
GeneOntologyMolecularFunction	O-palmitoyltransferase activity	CPT1A CPT2	3.96e-04	5	127	2	GO:0016416
GeneOntologyMolecularFunction	purine ribonucleotide transmembrane transporter activity	SLC25A24 SLC25A25 SLC25A31	4.05e-04	23	127	3	GO:0005346
GeneOntologyMolecularFunction	nuclear retinoid X receptor binding	NSD1 NCOR1 NCOA1	4.05e-04	23	127	3	GO:0046965
GeneOntologyMolecularFunction	phosphate transmembrane transporter activity	SLC25A24 SLC17A2 SLC25A25	4.61e-04	24	127	3	GO:0005315
GeneOntologyMolecularFunction	carbohydrate derivative transmembrane transporter activity	SLC25A24 SLC25A25 SLC5A2 SLC25A31	5.42e-04	59	127	4	GO:1901505
GeneOntologyMolecularFunction	adenine nucleotide transmembrane transporter activity	SLC25A24 SLC25A25 SLC25A31	5.87e-04	26	127	3	GO:0000295
GeneOntologyMolecularFunction	carnitine O-acyltransferase activity	CPT1A CPT2	5.92e-04	6	127	2	GO:0016406
GeneOntologyMolecularFunction	dynein light intermediate chain binding	DYNC2H1 DNAH9 DYNC1H1	7.33e-04	28	127	3	GO:0051959
GeneOntologyMolecularFunction	sodium ion transmembrane transporter activity	SLC17A2 SLC5A2 SLC8B1 SCN10A SCNN1B SLC13A5	7.95e-04	171	127	6	GO:0015081
GeneOntologyMolecularFunction	purine nucleotide transmembrane transporter activity	SLC25A24 SLC25A25 SLC25A31	8.14e-04	29	127	3	GO:0015216
GeneOntologyMolecularFunction	organophosphate:phosphate antiporter activity	SLC25A24 SLC25A25	8.25e-04	7	127	2	GO:0015315
GeneOntologyMolecularFunction	nucleotide transmembrane transporter activity	SLC25A24 SLC25A25 SLC25A31	1.19e-03	33	127	3	GO:0015215
GeneOntologyMolecularFunction	dynein intermediate chain binding	DYNC2H1 DNAH9 DYNC1H1	1.67e-03	37	127	3	GO:0045505
GeneOntologyCellularComponent	SLIK (SAGA-like) complex	TAF6L TAF6	1.15e-04	3	130	2	GO:0046695
HumanPheno	Long philtrum	SLC25A24 COMT DYNC2H1 HECTD4 KCNAB2 NSD1 BBS2 NF1 KMT2A TAF6 MAP2K1 MAP2K2 CDH2 NIPBL DSE	3.60e-06	429	47	15	HP:0000343
HumanPheno	Cryptorchidism	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM NF1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 NIPBL DSE	6.33e-06	780	47	20	HP:0000028
HumanPheno	Abnormal spermatogenesis	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM MSH5 EYS SYCP2 NF1 MOV10L1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 DNAH9 NIPBL DSE	8.34e-06	1190	47	25	HP:0008669
HumanPheno	Azoospermia	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM MSH5 EYS NF1 MOV10L1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 DNAH9 NIPBL DSE	1.88e-05	1157	47	24	HP:0000027
HumanPheno	Abnormal male internal genitalia morphology	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM MSH5 EYS SYCP2 NF1 MOV10L1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 DNAH9 NIPBL DSE	1.89e-05	1243	47	25	HP:0000022
HumanPheno	Conductive hearing impairment	TBX22 SLC25A24 ZBTB20 COMT KCNAB2 NSD1 BBS2 POMGNT1 EFTUD2 EYS NF1 DNAH9 NIPBL	2.01e-05	373	47	13	HP:0000405
HumanPheno	Downslanted palpebral fissures	SLC25A24 ZBTB20 COMT HECTD4 NSD1 BBS2 EFTUD2 NF1 KMT2A SLC13A5 MAP2K1 MAP2K2 CDH2 DYNC1H1 DSE	2.20e-05	497	47	15	HP:0000494
HumanPheno	Functional abnormality of male internal genitalia	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM MSH5 EYS SYCP2 NF1 MOV10L1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 DNAH9 NIPBL DSE	2.77e-05	1269	47	25	HP:0000025
HumanPheno	Functional abnormality of the middle ear	TBX22 SLC25A24 ZBTB20 COMT KCNAB2 NSD1 BBS2 POMGNT1 EFTUD2 EYS NF1 DNAH9 NIPBL	2.90e-05	386	47	13	HP:0011452
HumanPheno	Abnormal testis morphology	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM MSH5 EYS NF1 MOV10L1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 NIPBL DSE	4.44e-05	1129	47	23	HP:0000035
HumanPheno	Non-obstructive azoospermia	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM MSH5 EYS NF1 MOV10L1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 NIPBL DSE	4.65e-05	1132	47	23	HP:0011961
HumanPheno	Posteriorly rotated ears	SLC25A24 KCNAB2 NSD1 BBS2 POMGNT1 ESAM CPT2 NF1 COG5 MAP2K1 MAP2K2 CDH2 NIPBL DSE	5.23e-05	470	47	14	HP:0000358
HumanPheno	Abnormal male reproductive system physiology	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM MSH5 EYS SYCP2 NF1 MOV10L1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 DNAH9 NIPBL DSE	5.23e-05	1314	47	25	HP:0012874
HumanPheno	Low posterior hairline	SLC25A24 NF1 KMT2A MAP2K1 MAP2K2 CDH2 NIPBL	8.28e-05	117	47	7	HP:0002162
HumanPheno	Abnormality of the posterior hairline	SLC25A24 NF1 KMT2A MAP2K1 MAP2K2 CDH2 NIPBL	8.28e-05	117	47	7	HP:0030141
HumanPheno	Abnormal cardiac septum morphology	TBX22 SLC25A24 EOGT COMT KCNAB2 NSD1 BBS2 ESAM EFTUD2 TTC7A NF1 KMT2A MAP2K1 MAP2K2 CDH2 DNAH9 NIPBL DSE	1.12e-04	787	47	18	HP:0001671
HumanPheno	Abnormality of the philtrum	SLC25A24 COMT DYNC2H1 HECTD4 KCNAB2 NSD1 BBS2 ESAM EFTUD2 NF1 KMT2A TAF6 MAP2K1 MAP2K2 CDH2 NIPBL DSE	1.42e-04	726	47	17	HP:0000288
HumanPheno	Abnormal internal genitalia	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM MSH5 EYS SYCP2 NF1 NBEAL2 MOV10L1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 DNAH9 NIPBL DSE	1.72e-04	1498	47	26	HP:0000812
HumanPheno	Medial flaring of the eyebrow	SLC25A24 ZBTB20 HECTD4 BBS2 ESAM KMT2A TAF6 CDH2 NIPBL	1.89e-04	228	47	9	HP:0010747
HumanPheno	Abnormal bleeding	TBXA2R EOGT COMT ESAM CUBN CPT2 IKZF5 TTC7A NF1 NBEAL2 MAP2K1 MAP2K2 ABCG8 DSE	2.23e-04	537	47	14	HP:0001892
HumanPheno	Atrial septal defect	TBX22 SLC25A24 EOGT COMT NSD1 BBS2 ESAM EFTUD2 NF1 KMT2A MAP2K1 MAP2K2 NIPBL DSE	2.42e-04	541	47	14	HP:0001631
HumanPheno	Abnormality of the atrial septum	TBX22 SLC25A24 EOGT COMT NSD1 BBS2 ESAM EFTUD2 NF1 KMT2A MAP2K1 MAP2K2 NIPBL DSE	2.42e-04	541	47	14	HP:0001630
HumanPheno	Abnormality of the male genitalia	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM MSH5 EYS SYCP2 NF1 MOV10L1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 DNAH9 NIPBL DSE	2.54e-04	1437	47	25	HP:0010461
HumanPheno	Abnormal atrial septum morphology	TBX22 SLC25A24 EOGT COMT NSD1 BBS2 ESAM EFTUD2 NF1 KMT2A MAP2K1 MAP2K2 NIPBL DSE	2.56e-04	544	47	14	HP:0011994
HumanPheno	Abnormality of the hairline	SLC25A24 NSD1 NF1 KMT2A TAF6 COG5 MAP2K1 MAP2K2 CDH2 NIPBL	2.70e-04	294	47	10	HP:0009553
HumanPheno	Abnormal cardiac atrium morphology	TBX22 SLC25A24 EOGT COMT NSD1 BBS2 ESAM EFTUD2 NF1 KMT2A MAP2K1 MAP2K2 DNAH9 NIPBL DSE	2.71e-04	617	47	15	HP:0005120
HumanPheno	Hydrocephalus	SLC25A24 EOGT ZBTB20 COMT POMGNT1 ESAM CPT2 NF1 SLC13A5 MAP2K1 MAP2K2 DNAH9	3.13e-04	421	47	12	HP:0000238
HumanPheno	Synophrys	SLC25A24 ZBTB20 HECTD4 ESAM KMT2A TAF6 CDH2 NIPBL	3.47e-04	195	47	8	HP:0000664
HumanPheno	Abnormal palate morphology	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 HECTD4 NSD1 BBS2 POMGNT1 ESAM CPT2 EFTUD2 NF1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 NIPBL DSE	3.93e-04	1202	47	22	HP:0000174
HumanPheno	Abnormality of the scalp hair	SLC25A24 ZBTB20 NSD1 TTC7A NF1 KMT2A TAF6 COG5 MAP2K1 MAP2K2 CDH2 NIPBL	4.06e-04	433	47	12	HP:0100037
HumanPheno	Impaired platelet aggregation	TBXA2R IKZF5 NBEAL2 ABCG8	4.13e-04	39	47	4	HP:0003540
HumanPheno	Abnormal cerebral ventricle morphology	SLC25A24 EOGT ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 POMGNT1 ESAM CPT2 NDUFS8 NF1 SLC13A5 COG5 MAP2K1 MAP2K2 CDH2 DNAH9 NIPBL DSE	4.84e-04	1046	47	20	HP:0002118
HumanPheno	Broad forehead	SLC25A24 ZBTB20 HECTD4 NSD1 ESAM NF1 MAP2K1 CDH2	4.87e-04	205	47	8	HP:0000337
HumanPheno	Superior pectus carinatum	NF1 MAP2K1	4.94e-04	4	47	2	HP:0000917
HumanPheno	Neurofibrosarcoma	NF1 MAP2K1	4.94e-04	4	47	2	HP:0100697
HumanPheno	Abnormal number of alpha granules	IKZF5 NBEAL2	4.94e-04	4	47	2	HP:0012528
HumanPheno	Abnormal platelet aggregation	TBXA2R IKZF5 NBEAL2 ABCG8	5.02e-04	41	47	4	HP:0030402
HumanPheno	Facial hypertrichosis	SLC25A24 ZBTB20 HECTD4 ESAM KMT2A TAF6 CDH2 NIPBL	5.03e-04	206	47	8	HP:0002219
HumanPheno	Hydronephrosis	DYNC2H1 KCNAB2 NSD1 BBS2 CPT2 NF1 MAP2K1 MAP2K2 DSE	5.64e-04	264	47	9	HP:0000126
HumanPheno	Abnormal scalp morphology	SLC25A24 ZBTB20 NSD1 TTC7A NF1 KMT2A TAF6 COG5 MAP2K1 MAP2K2 CDH2 NIPBL	5.78e-04	450	47	12	HP:0001965
HumanPheno	Slanting of the palpebral fissure	SLC25A24 ZBTB20 COMT HECTD4 NSD1 BBS2 ESAM EFTUD2 NF1 KMT2A SLC13A5 MAP2K1 MAP2K2 CDH2 DYNC1H1 DSE	6.01e-04	739	47	16	HP:0200006
HumanPheno	Abnormal helix morphology	COMT CPT2 EFTUD2 NF1 MAP2K1 MAP2K2 CDH2 NIPBL	6.10e-04	212	47	8	HP:0011039
HumanPheno	Abnormal male external genitalia morphology	TBX22 SLC25A24 ZBTB20 COMT DYNC2H1 KCNAB2 NSD1 BBS2 POMGNT1 ESAM MSH5 EYS NF1 MOV10L1 KMT2A FLRT3 TAF6 COG5 MAP2K1 MAP2K2 CDH2 NIPBL DSE	6.17e-04	1329	47	23	HP:0000032
HumanPheno	Congenital abnormal hair pattern	SLC25A24 NSD1 NF1 KMT2A TAF6 COG5 MAP2K1 MAP2K2 CDH2 NIPBL	6.33e-04	327	47	10	HP:0011361
HumanPheno	Macrotia	TBX22 ZBTB20 HECTD4 NSD1 BBS2 MAP2K1 MAP2K2 NIPBL DSE	6.83e-04	271	47	9	HP:0000400
HumanPheno	Abnormal eyebrow morphology	SLC25A24 ZBTB20 HECTD4 KCNAB2 NSD1 BBS2 ESAM TTC7A NF1 KMT2A TAF6 MAP2K1 MAP2K2 CDH2 NIPBL	7.11e-04	674	47	15	HP:0000534
HumanPheno	Abnormal hair pattern	SLC25A24 ZBTB20 HECTD4 KCNAB2 NSD1 BBS2 ESAM NF1 KMT2A TAF6 COG5 MAP2K1 MAP2K2 CDH2 NIPBL	7.34e-04	676	47	15	HP:0010720
HumanPheno	Abnormal alpha granules	IKZF5 NBEAL2	8.19e-04	5	47	2	HP:0012483
Domain	LRRC37AB_C	LRRC37A3 LRRC37A2 LRRC37A	1.22e-06	4	127	3	IPR029423
Domain	LRRC37AB_C	LRRC37A3 LRRC37A2 LRRC37A	1.22e-06	4	127	3	PF14914
Domain	LRRC37_N	LRRC37A3 LRRC37A2 LRRC37A	1.22e-06	4	127	3	IPR032754
Domain	LRRC37	LRRC37A3 LRRC37A2 LRRC37A	1.22e-06	4	127	3	PF15779
Domain	LRRC37A/B-like	LRRC37A3 LRRC37A2 LRRC37A	1.22e-06	4	127	3	IPR015753
Domain	VWA_3	VWA5B2 ITIH5 VWA5A	1.68e-05	8	127	3	PF13768
Domain	DHC_N1	DYNC2H1 DNAH9 DYNC1H1	1.68e-05	8	127	3	PF08385
Domain	Dynein_heavy_dom-1	DYNC2H1 DNAH9 DYNC1H1	1.68e-05	8	127	3	IPR013594
Domain	VIT	VWA5B2 ITIH5 VWA5A	3.56e-05	10	127	3	PS51468
Domain	VIT	VWA5B2 ITIH5 VWA5A	3.56e-05	10	127	3	IPR013694
Domain	TAF6_C	TAF6L TAF6	4.59e-05	2	127	2	IPR011442
Domain	TAF6_C	TAF6L TAF6	4.59e-05	2	127	2	PF07571
Domain	TAF	TAF6L TAF6	4.59e-05	2	127	2	PF02969
Domain	Dynein_heavy_chain_D4_dom	DYNC2H1 DNAH9 DYNC1H1	1.06e-04	14	127	3	IPR024317
Domain	Dynein_HC_stalk	DYNC2H1 DNAH9 DYNC1H1	1.06e-04	14	127	3	IPR024743
Domain	Dynein_heavy_dom-2	DYNC2H1 DNAH9 DYNC1H1	1.06e-04	14	127	3	IPR013602
Domain	DHC_N2	DYNC2H1 DNAH9 DYNC1H1	1.06e-04	14	127	3	PF08393
Domain	ATPase_dyneun-rel_AAA	DYNC2H1 DNAH9 DYNC1H1	1.06e-04	14	127	3	IPR011704
Domain	MT	DYNC2H1 DNAH9 DYNC1H1	1.06e-04	14	127	3	PF12777
Domain	AAA_8	DYNC2H1 DNAH9 DYNC1H1	1.06e-04	14	127	3	PF12780
Domain	AAA_5	DYNC2H1 DNAH9 DYNC1H1	1.06e-04	14	127	3	PF07728
Domain	DHC_fam	DYNC2H1 DNAH9 DYNC1H1	1.32e-04	15	127	3	IPR026983
Domain	Dynein_heavy	DYNC2H1 DNAH9 DYNC1H1	1.32e-04	15	127	3	PF03028
Domain	Dynein_heavy_dom	DYNC2H1 DNAH9 DYNC1H1	1.32e-04	15	127	3	IPR004273
Domain	TAF_TATA-bd	TAF6L TAF6	1.37e-04	3	127	2	IPR004823
Domain	TAF	TAF6L TAF6	1.37e-04	3	127	2	SM00803
Domain	HATPase_c	MORC4 TRAP1 TOP2A	2.33e-04	18	127	3	SM00387
Domain	Graves_DC	SLC25A24 SLC25A25	2.73e-04	4	127	2	IPR002167
Domain	HATPase_c	MORC4 TRAP1 TOP2A	2.75e-04	19	127	3	PF02518
Domain	-	MORC4 TRAP1 TOP2A	3.22e-04	20	127	3	3.30.565.10
Domain	HATPase_C	MORC4 TRAP1 TOP2A	3.73e-04	21	127	3	IPR003594
Domain	Carn_acyl_trans	CPT1A CPT2	9.42e-04	7	127	2	IPR000542
Domain	Carn_acyltransf	CPT1A CPT2	9.42e-04	7	127	2	PF00755
Domain	ACYLTRANSF_C_1	CPT1A CPT2	9.42e-04	7	127	2	PS00439
Domain	ACYLTRANSF_C_2	CPT1A CPT2	9.42e-04	7	127	2	PS00440
Domain	VIT	ITIH5 VWA5A	1.25e-03	8	127	2	PF08487
Domain	VIT	ITIH5 VWA5A	1.25e-03	8	127	2	SM00609
Domain	Mit_carrier	SLC25A24 SLC25A25 SLC25A31	1.32e-03	32	127	3	IPR002067
Domain	Ribosomal_S5_D2-typ_fold	EFTUD2 TRAP1 TOP2A	1.58e-03	34	127	3	IPR020568
Domain	VWF_A	VWA5B2 ITIH5 VWA5A VWA2	4.67e-03	99	127	4	IPR002035
Domain	Post-SET_dom	NSD1 KMT2A	5.17e-03	16	127	2	IPR003616
Domain	PostSET	NSD1 KMT2A	5.17e-03	16	127	2	SM00508
Domain	POST_SET	NSD1 KMT2A	5.17e-03	16	127	2	PS50868
Domain	-	SLC25A24 SLC25A25 SLC25A31	5.61e-03	53	127	3	1.50.40.10
Domain	Mito_carr	SLC25A24 SLC25A25 SLC25A31	5.61e-03	53	127	3	PF00153
Domain	SOLCAR	SLC25A24 SLC25A25 SLC25A31	5.61e-03	53	127	3	PS50920
Domain	Mitochondrial_sb/sol_carrier	SLC25A24 SLC25A25 SLC25A31	5.61e-03	53	127	3	IPR018108
Domain	Mt_carrier_dom	SLC25A24 SLC25A25 SLC25A31	5.61e-03	53	127	3	IPR023395
Domain	LRR_8	LRRC37A3 LRRC37A2 LRRC4 LRRC37A FLRT3	6.29e-03	171	127	5	PF13855
Domain	EFTu-like_2	GTPBP1 EFTUD2	6.54e-03	18	127	2	IPR004161
Domain	GTP_EFTU_D2	GTPBP1 EFTUD2	6.54e-03	18	127	2	PF03144
Domain	G_TR_2	GTPBP1 EFTUD2	6.54e-03	18	127	2	PS51722
Domain	VWA	ITIH5 VWA5A VWA2	6.55e-03	56	127	3	PF00092
Pubmed	Primate segmental duplication creates novel promoters for the LRRC37 gene family within the 17q21.31 inversion polymorphism region.	LRRC37A3 LRRC37A2 LRRC37A	2.18e-07	4	133	3	22419166
Pubmed	RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.	NF1 MAP2K1 MAP2K2	5.44e-07	5	133	3	23423222
Pubmed	The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.	POMGNT1 ESAM RDH13 CYP2S1 SLC25A25 LRRC4 SNAP47 ITIH5 CEACAM19 CASP12 EYS DGAT2 NBEAL2 DHRSX FLRT3 IL17RB	1.23e-06	985	133	16	12975309
Pubmed	A multi-factor trafficking site on the spliceosome remodeling enzyme BRR2 recruits C9ORF78 to regulate alternative splicing.	IPO7 PSMD3 NDUFS8 EFTUD2 NCOR1 TRAP1 UBXN4 NDC1 ANAPC2 COG5 TOP2A DYNC1H1	1.77e-06	560	133	12	35241646
Pubmed	Direct interaction between hnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice.	IPO7 PSMD3 GTPBP1 EFTUD2 TRAP1 NF1 ANAPC2 PKN2 MAP2K2 NIPBL TOP2A DYNC1H1	2.63e-06	582	133	12	20467437
Pubmed	Evolutionary dynamism of the primate LRRC37 gene family.	LRRC37A3 LRRC37A2 LRRC37A	6.43e-06	10	133	3	23064749
Pubmed	RUFY1 binds Arl8b and mediates endosome-to-TGN CI-M6PR retrieval for cargo sorting to lysosomes.	IPO7 COMT PSMD3 NDUFS8 EFTUD2 NCOR1 TRAP1 KMT2A DYNC1H1	7.58e-06	344	133	9	36282215
Pubmed	Spatial Chromosome Folding and Active Transcription Drive DNA Fragility and Formation of Oncogenic MLL Translocations.	KMT2A TOP2A	1.45e-05	2	133	2	31202576
Pubmed	Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.	MAP2K1 MAP2K2	1.45e-05	2	133	2	9563949
Pubmed	Mek2 is dispensable for mouse growth and development.	MAP2K1 MAP2K2	1.45e-05	2	133	2	12832465
Pubmed	Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.	MAP2K1 MAP2K2	1.45e-05	2	133	2	19014680
Pubmed	Neurofibromin interacts with the cytoplasmic Dynein Heavy Chain 1 in melanosomes of human melanocytes.	NF1 DYNC1H1	1.45e-05	2	133	2	23583712
Pubmed	Identification of voltage-gated K(+) channel beta 2 (Kvβ2) subunit as a novel interaction partner of the pain transducer Transient Receptor Potential Vanilloid 1 channel (TRPV1).	TRPV1 KCNAB2	1.45e-05	2	133	2	24036102
Pubmed	Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.	MAP2K1 MAP2K2	1.45e-05	2	133	2	26625317
Pubmed	Genetic analysis of the cytoplasmic dynein subunit families.	DYNC2H1 DYNC1H1	1.45e-05	2	133	2	16440056
Pubmed	Genetic variation in salt taste receptors impact salt intake and blood pressure.	TRPV1 SCNN1B	1.45e-05	2	133	2	36899055
Pubmed	Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation.	MAP2K1 MAP2K2	1.45e-05	2	133	2	21699731
Pubmed	Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia.	MAP2K1 MAP2K2	1.45e-05	2	133	2	17419998
Pubmed	MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response.	MAP2K1 MAP2K2	1.45e-05	2	133	2	23735655
Pubmed	The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.	MAP2K1 MAP2K2	1.45e-05	2	133	2	35069558
Pubmed	The Leydig cell MEK/ERK pathway is critical for maintaining a functional population of adult Leydig cells and for fertility.	MAP2K1 MAP2K2	1.45e-05	2	133	2	21527500
Pubmed	Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia.	MAP2K1 MAP2K2	1.45e-05	2	133	2	19383924
Pubmed	MEK1 and MEK2, different regulators of the G1/S transition.	MAP2K1 MAP2K2	1.45e-05	2	133	2	15284233
Pubmed	Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.	MAP2K1 MAP2K2	1.45e-05	2	133	2	19156172
Pubmed	p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2.	MAP2K1 MAP2K2	1.45e-05	2	133	2	12839928
Pubmed	MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.	MAP2K1 MAP2K2	1.45e-05	2	133	2	16957420
Pubmed	Human liver mitochondrial carnitine palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene.	CPT1A CPT2	1.45e-05	2	133	2	7892212
Pubmed	T cell adhesion primes antigen receptor-induced calcium responses through a transient rise in adenosine 3',5'-cyclic monophosphate.	MAP2K1 MAP2K2	1.45e-05	2	133	2	19144315
Pubmed	Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.	MAP2K1 MAP2K2	1.45e-05	2	133	2	19500021
Pubmed	Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.	MAP2K1 MAP2K2	1.45e-05	2	133	2	22197931
Pubmed	Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.	MAP2K1 MAP2K2	1.45e-05	2	133	2	27956260
Pubmed	Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.	MAP2K1 MAP2K2	1.45e-05	2	133	2	17981815
Pubmed	Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells.	MAP2K1 MAP2K2	1.45e-05	2	133	2	28746311
Pubmed	Intrinsically active MEK variants are differentially regulated by proteinases and phosphatases.	MAP2K1 MAP2K2	1.45e-05	2	133	2	30087384
Pubmed	Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.	MAP2K1 MAP2K2	1.45e-05	2	133	2	22833572
Pubmed	ERK1/2 can feedback-regulate cellular MEK1/2 levels.	MAP2K1 MAP2K2	1.45e-05	2	133	2	26163823
Pubmed	Omics profiling identifies the regulatory functions of the MAPK/ERK pathway in nephron progenitor metabolism.	MAP2K1 MAP2K2	1.45e-05	2	133	2	36189831
Pubmed	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.	MAP2K1 MAP2K2	1.45e-05	2	133	2	22805292
Pubmed	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.	MAP2K1 MAP2K2	1.45e-05	2	133	2	22805291
Pubmed	Biphasic regulation of osteoblast development via the ERK MAPK-mTOR pathway.	MAP2K1 MAP2K2	1.45e-05	2	133	2	35975983
Pubmed	Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc.	MAP2K1 MAP2K2	1.45e-05	2	133	2	16162927
Pubmed	Regulation of intracellular MEK1/2 translocation in mouse oocytes: cytoplasmic dynein/dynactin-mediated poleward transport and cyclin B degradation-dependent release from spindle poles.	MAP2K1 MAP2K2	1.45e-05	2	133	2	17507801
Pubmed	Reduced thermal sensitivity and Nav1.8 and TRPV1 channel expression in sensory neurons of aged mice.	TRPV1 SCN10A	1.45e-05	2	133	2	15979214
Pubmed	Inhibition of microtubules and dynein rescues human immunodeficiency virus type 1 from owl monkey TRIMCyp-mediated restriction in a cellular context-specific fashion.	DYNC2H1 DYNC1H1	1.45e-05	2	133	2	25502651
Pubmed	Activation of two isoforms of mitogen-activated protein kinase kinase in response to epidermal growth factor and nerve growth factor.	MAP2K1 MAP2K2	1.45e-05	2	133	2	8529659
Pubmed	Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product.	MAP2K1 MAP2K2	1.45e-05	2	133	2	1381507
Pubmed	[Mek1 and Mek2 functions in the formation of the blood placental barrier].	MAP2K1 MAP2K2	1.45e-05	2	133	2	22549869
Pubmed	The ERK1/2 pathway regulates testosterone synthesis by coordinately regulating the expression of steroidogenic genes in Leydig cells.	MAP2K1 MAP2K2	1.45e-05	2	133	2	23480967
Pubmed	Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.	MAP2K1 MAP2K2	1.45e-05	2	133	2	23237773
Pubmed	Cisplatin inhibits MEK1/2.	MAP2K1 MAP2K2	1.45e-05	2	133	2	26155939
Pubmed	Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin.	MAP2K1 MAP2K2	1.45e-05	2	133	2	19198628
Pubmed	Mitogen-activated protein kinase (MAPK)-docking sites in MAPK kinases function as tethers that are crucial for MAPK regulation in vivo.	MAP2K1 MAP2K2	1.45e-05	2	133	2	15979847
Pubmed	ERK (MAPK) does not phosphorylate tau under physiological conditions in vivo or in vitro.	MAP2K1 MAP2K2	1.45e-05	2	133	2	25491074
Pubmed	Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2.	MAP2K1 MAP2K2	1.45e-05	2	133	2	20172001
Pubmed	Chromosome mapping of the human genes encoding the MAP kinase kinase MEK1 (MAP2K1) to 15q21 and MEK2 (MAP2K2) to 7q32.	MAP2K1 MAP2K2	1.45e-05	2	133	2	10828601
Pubmed	Implication of MEK1 and MEK2 in the establishment of the blood-placenta barrier during placentogenesis in mouse.	MAP2K1 MAP2K2	1.45e-05	2	133	2	22561024
Pubmed	Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.	MAP2K1 MAP2K2	1.45e-05	2	133	2	15543157
Pubmed	Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.	MAP2K1 MAP2K2	1.45e-05	2	133	2	18390968
Pubmed	Multiple mouse chromosomal loci for dynein-based motility.	DYNC2H1 NF1 DNAH9 DYNC1H1	3.21e-05	47	133	4	8812413
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	IPO7 LRRC37A3 DYNC2H1 JAGN1 MORC4 NCOR1 NF1 SYNE2 NCOA1 MAP2K2 NIPBL	3.64e-05	638	133	11	31182584
Pubmed	Large-scale proteomics and phosphoproteomics of urinary exosomes.	PDE8A COMT DYNC2H1 ANXA7 PSMD3 CUBN SLC5A2 EYS EML5 PTPRO TMPRSS11D SCN10A NIPBL DYNC1H1	3.68e-05	1016	133	14	19056867
Pubmed	A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.	KNTC1 USP34 IPO7 ANXA7 PSMD3 PGAP4 RDH13 SNAP47 NDUFS8 EFTUD2 TRAP1 NDC1 SYNE2 KMT2A COG5 TOP2A DYNC1H1	3.70e-05	1440	133	17	30833792
Pubmed	AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.	CPT1A CPT2 STRADB	4.28e-05	18	133	3	16054041
Pubmed	Roles of ASIC3, TRPV1, and NaV1.8 in the transition from acute to chronic pain in a mouse model of fibromyalgia.	TRPV1 SCN10A	4.34e-05	3	133	2	24957987
Pubmed	Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector.	MAP2K1 MAP2K2	4.34e-05	3	133	2	10489373
Pubmed	Nuclear receptor coregulators differentially modulate induction and glucocorticoid receptor-mediated repression of the corticotropin-releasing hormone gene.	NCOR1 NCOA1	4.34e-05	3	133	2	18006628
Pubmed	Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.	MAP2K1 MAP2K2	4.34e-05	3	133	2	25600339
Pubmed	Regulation of skeletal muscle insulin-stimulated signaling through the MEK-REDD1-mTOR axis.	MAP2K1 MAP2K2	4.34e-05	3	133	2	27913296
Pubmed	MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.	KMT2A MAP2K1	4.34e-05	3	133	2	27588400
Pubmed	Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.	MAP2K1 MAP2K2	4.34e-05	3	133	2	22393900
Pubmed	Cytoplasmic dynein promotes HIV-1 uncoating.	DYNC2H1 DYNC1H1	4.34e-05	3	133	2	25375884
Pubmed	Genomic structure of and a cardiac promoter for the mouse carnitine palmitoyltransferase II gene.	CPT1A CPT2	4.34e-05	3	133	2	8307575
Pubmed	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.	MAP2K1 MAP2K2	4.34e-05	3	133	2	25722381
Pubmed	CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation.	CPT1A CPT2	4.34e-05	3	133	2	31151054
Pubmed	Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.	MAP2K1 MAP2K2	4.34e-05	3	133	2	18413255
Pubmed	Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions.	MAP2K1 MAP2K2	4.34e-05	3	133	2	23626836
Pubmed	Mammalian cells express three distinct dynein heavy chains that are localized to different cytoplasmic organelles.	DYNC2H1 DYNC1H1	4.34e-05	3	133	2	8666668
Pubmed	Dissociation of steroid receptor coactivator 1 and nuclear receptor corepressor recruitment to the human glucocorticoid receptor by modification of the ligand-receptor interface: the role of tyrosine 735.	NCOR1 NCOA1	4.34e-05	3	133	2	12569182
Pubmed	The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation.	MAP2K1 MAP2K2	4.34e-05	3	133	2	34715128
Pubmed	CPEB3 Deficiency Elevates TRPV1 Expression in Dorsal Root Ganglia Neurons to Potentiate Thermosensation.	TRPV1 SCN10A	4.34e-05	3	133	2	26915043
Pubmed	Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1.	MAP2K1 MAP2K2	4.34e-05	3	133	2	11823456
Pubmed	Etomoxir Inhibits Macrophage Polarization by Disrupting CoA Homeostasis.	CPT1A CPT2	4.34e-05	3	133	2	30043752
Pubmed	MEK1 dependent and independent ERK activation regulates IL-10 and IL-12 production in bone marrow derived macrophages.	MAP2K1 MAP2K2	4.34e-05	3	133	2	26208884
Pubmed	Mitogen-activated protein kinase kinase 1/2 inhibition and angiotensin II converting inhibition in mice with cardiomyopathy caused by lamin A/C gene mutation.	MAP2K1 MAP2K2	4.34e-05	3	133	2	25218145
Pubmed	Identification of a novel human subfamily of mitochondrial carriers with calcium-binding domains.	SLC25A24 SLC25A25	4.34e-05	3	133	2	15054102
Pubmed	Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.	MAP2K1 MAP2K2	4.34e-05	3	133	2	16439621
Pubmed	Privileged crosstalk between TRPV1 channels and mitochondrial calcium shuttling machinery controls nociception.	TRPV1 SLC8B1	4.34e-05	3	133	2	27627464
Pubmed	MEK1/2 activity modulates TREM2 cell surface recruitment.	MAP2K1 MAP2K2	4.34e-05	3	133	2	33839686
Pubmed	MEK1,2 response element mediates angiotensin II-stimulated plasminogen activator inhibitor-1 promoter activation.	MAP2K1 MAP2K2	4.34e-05	3	133	2	14656894
Pubmed	Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression.	MAP2K1 MAP2K2	4.34e-05	3	133	2	24746703
Pubmed	[Association between genetic variations and functional dyspepsia].	TRPV1 SCN10A	4.34e-05	3	133	2	23047628
Pubmed	Is diagnosing cardio-facio-cutaneous (CFC) syndrome still a challenge? Delineation of the phenotype in 15 Polish patients with proven mutations, including novel mutations in the BRAF1 gene.	MAP2K1 MAP2K2	4.34e-05	3	133	2	25463315
Pubmed	Thyroid hormone signaling in vivo requires a balance between coactivators and corepressors.	NCOR1 NCOA1	4.34e-05	3	133	2	24550004
Pubmed	Nociceptor sensory neurons suppress neutrophil and γδ T cell responses in bacterial lung infections and lethal pneumonia.	TRPV1 SCN10A	4.34e-05	3	133	2	29505031
Pubmed	Recombinant human cytoplasmic dynein heavy chain 1 and 2: observation of dynein-2 motor activity in vitro.	DYNC2H1 DYNC1H1	4.34e-05	3	133	2	21723285
Pubmed	Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.	MAP2K1 MAP2K2	4.34e-05	3	133	2	18060073
Pubmed	Mitogen-activated protein kinase kinases promote mitochondrial biogenesis in part through inducing peroxisome proliferator-activated receptor γ coactivator-1β expression.	MAP2K1 MAP2K2	4.34e-05	3	133	2	21458501
Pubmed	Inhibition by etomoxir of rat liver carnitine octanoyltransferase is produced through the co-ordinate interaction with two histidine residues.	CPT1A CPT2	4.34e-05	3	133	2	11023836
Pubmed	p38mapk and MEK1/2 inhibition contribute to cellular oxidant injury after hypoxia.	MAP2K1 MAP2K2	4.34e-05	3	133	2	14672918
Pubmed	Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim.	MAP2K1 MAP2K2	4.34e-05	3	133	2	20885957
GeneFamily	O-linked N-acetylglucosaminyltransferases\|Tetratricopeptide repeat domain containing	EOGT POMGNT1	1.53e-04	4	92	2	446
GeneFamily	Mitogen-activated protein kinase kinases	MAP2K1 MAP2K2	5.29e-04	7	92	2	653
GeneFamily	Solute carriers	SLC25A24 SLC17A2 SLC25A25 SLC48A1 SLC5A2 SLC8B1 SLC13A5 SLC25A31	9.10e-04	395	92	8	752
GeneFamily	Dyneins, cytoplasmic	DYNC2H1 DYNC1H1	1.93e-03	13	92	2	538
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	SLC25A24 USP34 ZBTB20 PDE8A IPO7 SOCS6 PTPN4 SYNE2 NCOA1 PKN2 TRAM2 COG5 MAP2K1 CDH2 NIPBL TOP2A	5.49e-06	856	130	16	M4500
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DYNC2H1 NSD1 TTLL7 NCOR1 NCOA1 KMT2A CDH2 DYNC1H1	1.18e-07	195	131	8	3e519cffa6144a62b06124642a14c9ff39b76554
ToppCell	mLN-Macrophage-LYVE1_Macrophage\|Macrophage / Region, Cell class and subclass	COMT KCNAB2 NSD1 RTN3 UBXN4 SLC8B1 PKN2 DYNC1H1	1.44e-07	200	131	8	e3c15e0e1c2602b0cc9ab8cc50c978d265350c94
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	USP34 ZBTB20 NF1 SYNE2 KMT2A NIPBL DYNC1H1	1.43e-06	188	131	7	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DYNC2H1 TTLL7 NCOR1 NCOA1 KMT2A CDH2 DYNC1H1	1.83e-06	195	131	7	7796ea9247f4c63762f0de8490fed08b9717fa23
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	VWA5B2 DYNC2H1 DNAI3 LRRC4 SYNE2 FRMPD2B DNAH9	1.96e-06	197	131	7	74a2c6cb8fcfe53dd9a2b36492a16c58f38e51c9
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	USP34 ZBTB20 LRRC37A3 NF1 NCOA1 SSH2 COG5	2.09e-06	199	131	7	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ZBTB20 CUBN SLC5A2 SYNE2 FLRT3 CDH2 IL17RB	2.16e-06	200	131	7	105564ee05bd11685b5747ee32d5350cf3c2e2e1
ToppCell	PND07-28-samps-Mesenchymal-Pericyte-pericyte_F\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	NMUR1 PTPN4 GUCY1B1 SCN10A VWA2 CDH2	5.51e-06	150	131	6	2d0d6dc07dcfe28e3d7694c52d15d17dae2fd47b
ToppCell	PND07-28-samps-Mesenchymal-Pericyte\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	NMUR1 PTPN4 GUCY1B1 SCN10A VWA2 CDH2	5.51e-06	150	131	6	5b111ec11a642d63fafa7e1422e36f81a2776531
ToppCell	facs-Brain_Myeloid-Striatum-24m-Myeloid-macrophage\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC25A24 CYP2S1 GTPBP1 PTPN4 NBEAL2 FLRT3	1.42e-05	177	131	6	f6b9d91d46830d0d207b0abd4ee5a4942fd99774
ToppCell	NS-critical-d_07-13-Epithelial-Ionocyte\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	FAT3 BEST3 ITIH5 MOV10L1 SCNN1B CDH2	1.71e-05	183	131	6	ba43bca2b45be1008eebd3f033cecb061fb3a966
ToppCell	COVID-19-kidney-PCT-S1\|kidney / Disease (COVID-19 only), tissue and cell type	CUBN AGBL3 SYNE2 FLRT3 CDH2 IL17RB	1.76e-05	184	131	6	51ed1ebfdef45149541917c66cbacad87072e51f
ToppCell	3'-Broncho-tracheal-Epithelial-Neuro-endocrine/ionocytic-ionocyte-Ionocyte-Ionocyte_L.0.7.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FAT3 BEST3 ITIH5 SYNE2 SCNN1B CDH2	1.76e-05	184	131	6	a60802e11dcc5f932811260b08a95a32f60f6b19
ToppCell	3'-Broncho-tracheal-Epithelial-Neuro-endocrine/ionocytic-ionocyte\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FAT3 BEST3 ITIH5 SYNE2 SCNN1B CDH2	1.76e-05	184	131	6	39c230d32e4259bc784e0edfd9e2884c96898564
ToppCell	3'-Broncho-tracheal-Epithelial-Neuro-endocrine/ionocytic-ionocyte-Ionocyte\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FAT3 BEST3 ITIH5 SYNE2 SCNN1B CDH2	1.76e-05	184	131	6	2a2fb691cc9414ef5b06c26239d2da03d6d7e5c2
ToppCell	critical-Epithelial-Ionocyte\|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	FAT3 BEST3 ITIH5 MOV10L1 SCNN1B CDH2	1.76e-05	184	131	6	58d36577eff814d46d72f031f3533d71549e3d6e
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_immature-Tip-like-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	VWA5B2 TBXA2R ESAM ITIH5 GPR146 BCL6B	1.88e-05	186	131	6	a906020a8df6fcca474b278f746c553b177a56b4
ToppCell	droplet-Bladder-nan\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NCOR1 UBXN4 SYNE2 PKN2 FLRT3 NIPBL	1.93e-05	187	131	6	663991a8afe652e92363b64bcbd68c14d0307f0e
ToppCell	critical-Epithelial-Ionocyte\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	FAT3 BEST3 ITIH5 MOV10L1 SCNN1B CDH2	2.11e-05	190	131	6	05a2c3549b68f49081723bf35db14974274419d5
ToppCell	PCW_13-14\|World / Celltypes from embryonic and fetal-stage human lung	ZBTB20 FAT3 ITIH5 NCOR1 CD22 NCOA1	2.11e-05	190	131	6	62a3ec1ae0829602b0569cc051210551644f1d46
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	USP34 ZBTB20 PDE8A SSH2 COG5 MAP2K1	2.31e-05	193	131	6	779276e775cb2492e8dd36436295a536084a6415
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Endothelial-Endothelial_mature-Endo_capilar-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	EOGT ESAM CPT1A ITIH5 GPR146 BCL6B	2.52e-05	196	131	6	889c9fed857f64664ca1f47fcec9fecb15ed103c
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	USP34 ESAM SYNE2 KMT2A FAM135A NIPBL	2.82e-05	200	131	6	dccec522ab0d7fff62ad6273b02aa9022dbbb8eb
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ESAM ITIH5 GPR146 GUCY1B1 SYNE2 DYNC1H1	2.82e-05	200	131	6	89821a264e872ed53e08e9d3609d5cc5c314503e
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	ESAM ITIH5 GPR146 GUCY1B1 SYNE2 DYNC1H1	2.82e-05	200	131	6	79e51afb57ca38aacebd0298e5e727b55c0cfff9
ToppCell	mild\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	USP34 SYNE2 KMT2A PKN2 NIPBL DYNC1H1	2.82e-05	200	131	6	12f1685ce8f218433068e090c9d839cd5a1910bf
Disease	Malformations of Cortical Development, Group II	CDH2 DYNC1H1	1.90e-05	2	129	2	C1837249
Disease	Neurofibromatosis-Noonan syndrome	NF1 MAP2K2	1.90e-05	2	129	2	C2931482
Disease	pancreatitis	HECTD4 MORC4 ABCG8	4.38e-05	16	129	3	EFO_0000278
Disease	Cafe-au-lait macules with pulmonary stenosis	NF1 MAP2K2	5.67e-05	3	129	2	C0553586
Disease	small intestine adenocarcinoma (is_implicated_in)	MAP2K1 MAP2K2	5.67e-05	3	129	2	DOID:4906 (is_implicated_in)
Disease	Malignant neoplasm of breast	COMT DYNC2H1 LRRC37A2 CUBN CPT1A NCOR1 NF1 LRRC37A SYNE2 SCNN1B NCOA1 CDH2 DNAH9 NIPBL TOP2A	7.36e-05	1074	129	15	C0006142
Disease	Noonan Syndrome	NF1 MAP2K1 MAP2K2	1.54e-04	24	129	3	C0028326
Disease	Weaver syndrome	NSD1 KMT2A	1.88e-04	5	129	2	C0265210
Disease	lipid metabolism disorder (is_implicated_in)	CPT1A CPT2	2.81e-04	6	129	2	DOID:3146 (is_implicated_in)
Disease	Mammary Carcinoma, Human	COMT DYNC2H1 LRRC37A2 CPT1A NCOR1 LRRC37A NCOA1 CDH2 TOP2A	5.18e-04	525	129	9	C4704874
Disease	Mammary Neoplasms, Human	COMT DYNC2H1 LRRC37A2 CPT1A NCOR1 LRRC37A NCOA1 CDH2 TOP2A	5.18e-04	525	129	9	C1257931
Disease	Cornelia De Lange Syndrome	KMT2A NIPBL	5.22e-04	8	129	2	C0270972
Disease	microcephaly (is_implicated_in)	NSD1 EFTUD2	5.22e-04	8	129	2	DOID:10907 (is_implicated_in)
Disease	Mammary Neoplasms	COMT DYNC2H1 LRRC37A2 CPT1A NCOR1 LRRC37A NCOA1 CDH2 TOP2A	5.33e-04	527	129	9	C1458155
Disease	Breast Carcinoma	COMT DYNC2H1 LRRC37A2 CPT1A NCOR1 LRRC37A NCOA1 CDH2 TOP2A	6.17e-04	538	129	9	C0678222
Disease	Paroxysmal atrial fibrillation	USP34 BEST3 SYNE2 SCN10A COG5	6.29e-04	156	129	5	C0235480
Disease	familial atrial fibrillation	USP34 BEST3 SYNE2 SCN10A COG5	6.29e-04	156	129	5	C3468561
Disease	Persistent atrial fibrillation	USP34 BEST3 SYNE2 SCN10A COG5	6.29e-04	156	129	5	C2585653
Disease	RASopathy (implicated_via_orthology)	MAP2K1 MAP2K2	6.69e-04	9	129	2	DOID:0080690 (implicated_via_orthology)
Disease	Disorder of fatty acid metabolism	CPT1A CPT2	6.69e-04	9	129	2	cv:C0268634
Disease	Atrial Fibrillation	USP34 BEST3 SYNE2 SCN10A COG5	7.06e-04	160	129	5	C0004238
Disease	Cutaneous Melanoma	NF1 MAP2K1 MAP2K2	7.71e-04	41	129	3	C0151779
Disease	Noonan Syndrome 1	MAP2K1 MAP2K2	1.02e-03	11	129	2	C4551602
Disease	lignoceroylcarnitine (C24) measurement	CPT1A CPT2	1.02e-03	11	129	2	EFO_0800541
Disease	Turner Syndrome, Male	MAP2K1 MAP2K2	1.02e-03	11	129	2	C0041409
Disease	Female Pseudo-Turner Syndrome	MAP2K1 MAP2K2	1.02e-03	11	129	2	C1527404
Disease	non-high density lipoprotein cholesterol measurement	SLC17A2 USP34 COMT NSD1 EPX STRADB NDC1 SYNE2 COG5 ABCG8	1.19e-03	713	129	10	EFO_0005689
Disease	Leigh disease (implicated_via_orthology)	NDUFS8 PARL	1.22e-03	12	129	2	DOID:3652 (implicated_via_orthology)
Disease	acute myeloid leukemia (implicated_via_orthology)	KMT2A TOP2A	1.22e-03	12	129	2	DOID:9119 (implicated_via_orthology)
Disease	atrial fibrillation	USP34 BEST3 ABHD17C SYNE2 SCN10A PKN2 COG5	1.26e-03	371	129	7	EFO_0000275
Disease	total cholesterol measurement, triglyceride measurement, low density lipoprotein cholesterol measurement, high density lipoprotein cholesterol measurement	CPT1A NF1 TRAM2	1.30e-03	49	129	3	EFO_0004530, EFO_0004574, EFO_0004611, EFO_0004612
Disease	Leber congenital amaurosis (implicated_via_orthology)	RDH13 DHRSX	1.43e-03	13	129	2	DOID:14791 (implicated_via_orthology)
Disease	phosphatidylcholine measurement	PSMD3 DGAT2 SYNE2 NCOA1 CDH2 DYNC1H1	1.60e-03	284	129	6	EFO_0010226
Disease	leukemia	NF1 KMT2A TOP2A	1.81e-03	55	129	3	C0023418
Disease	acute graft vs. host disease, donor genotype effect measurement	SLC25A24 EYS	1.92e-03	15	129	2	EFO_0004599, EFO_0007892
Disease	RASopathy	NF1 MAP2K1	1.92e-03	15	129	2	cv:C5555857
Disease	Blood Platelet Disorders	TBXA2R ABCG8	2.19e-03	16	129	2	C0005818
Disease	Pheochromocytoma, Extra-Adrenal	COMT NF1	2.19e-03	16	129	2	C1257877
Disease	systolic blood pressure, alcohol drinking	COMT HECTD4 EYS GUCY1B1	2.45e-03	128	129	4	EFO_0004329, EFO_0006335
Disease	acute pancreatitis	MORC4 ABCG8	2.77e-03	18	129	2	EFO_1000652
Disease	matrix metalloproteinase 12 measurement	DYNC2H1 CASP12	2.77e-03	18	129	2	EFO_0010590
Disease	Noonan-Like Syndrome With Loose Anagen Hair	MAP2K1 MAP2K2	3.09e-03	19	129	2	C3501846
Disease	Noonan syndrome-like disorder with loose anagen hair	MAP2K1 MAP2K2	3.09e-03	19	129	2	C1843181
Disease	Cardio-facio-cutaneous syndrome	MAP2K1 MAP2K2	3.09e-03	19	129	2	C1275081
Disease	Costello syndrome (disorder)	MAP2K1 MAP2K2	3.09e-03	19	129	2	C0587248
Disease	superior temporal gyrus volume measurement	CUBN ITIH5	3.09e-03	19	129	2	EFO_0010331
Disease	Pheochromocytoma	COMT NF1	3.09e-03	19	129	2	C0031511
Disease	neutrophil count, basophil count	SLC25A24 HECTD4 PSMD3 TRAP1 NCOA1	3.10e-03	224	129	5	EFO_0004833, EFO_0005090
Disease	Malignant neoplasm of liver	ANXA7 NCOR1 PTPRO TOP2A	3.56e-03	142	129	4	C0345904
Disease	Liver neoplasms	ANXA7 NCOR1 PTPRO TOP2A	3.56e-03	142	129	4	C0023903
Disease	LEOPARD Syndrome	MAP2K1 MAP2K2	4.14e-03	22	129	2	C0175704

Protein segments in the cluster

Peptide	Gene	Start	Entry
SSVKAAQMPGRTLYR	nan	21	Q6ZS49
RSYRRQTSDSSMFLP	BEST3	411	Q8N1M1
FKEAVFSLLPRMRYG	EOGT	311	Q5NDL2
VNFTKPASLYSRGMR	AGBL3	226	Q8NEM8
MLRGVLFFSTPRTFQ	ANAPC2	156	Q9UJX6
LKMFLNLLSPRTSYR	GTPBP1	376	O00178
TAPLRMYNPTTTLNR	FLRT3	501	Q9NZU0
MASRVLSAYVSRLPA	NDUFAB1	1	O14561
IFSGRKPMLYSFQTS	CPT1A	156	P50416
TLAFIAQMRLPRTFS	ABCG8	166	Q9H221
IQFSRRTYKMPLGNL	ABCG8	606	Q9H221
MASSPAVLRASRLYQ	ACOT2	21	P49753
RSFPQLRATMEAYSR	ANXA7	371	P20073
ITYMISRKRSEFGAP	DNAI3	181	Q8IWG1
TQLPTIERLSMTRYF	CASP12	321	Q6UXS9
SSMPRVLSKRTYSFG	CCDC163	126	A0A0D9SF12
PLDMSQYFRLFNSTR	CPT2	211	P23786
NSFVGTRSYMSPERL	MAP2K1	221	Q02750
SFVGTRSYMAPERLQ	MAP2K2	226	P36507
RLMTAQNLVSYRSPG	NSD1	926	Q96L73
QYITRFCNPSRLMTG	RABGEF1	336	Q9UJ41
MTSRFRLPAGRTYNV	PTPN4	1	P29074
GTIIFMYLQPAKSRS	OR2G2	256	Q8NGZ5
SYLSRLMLSNRLPFS	LRRC37A3	1331	O60309
LLRAFSYMGFEVVRP	OAZ3	191	Q9UMX2
YGLNVSFLERLMSRP	MOV10L1	931	Q9BXT6
PNYRMRNLQFTTISL	EYS	2991	Q5T1H1
SYLSRLMLANRLPFS	LRRC37A2	1331	A6NM11
SYLSRLMLANRLPFS	LRRC37A	1331	A6NMS7
ANPVLYSLMSSRFRE	NMUR1	351	Q9HB89
SYRFLTPFTSMKLRG	ITIH5	611	Q86UX2
SFPRNNISYLVLSMI	JAGN1	91	Q8N5M9
RMGIFPESLARFYIA	LATS1	796	O95835
TLGTSEPYRMFTSRV	MTO1	481	Q9Y2Z2
SQTLPFMATRIGTFR	FER1L4	96	A9Z1Z3
VNFTTTPLGNRYMAL	IL17RB	196	Q9NRM6
MRTTRFRGYTLPQGT	CYP2S1	376	Q96SQ9
FREYLDGSSMIPVRL	EID2B	96	Q96D98
GFYQIRASMKIPSRI	FAM135A	26	Q9P2D6
VFPLFSSELGYMRAR	IPO7	461	O95373
LFMYIRPTSDRSPTQ	OR2M3	256	Q8NG83
RLRSGSASPMDLLSY	EPX	61	P11678
SVMPFISAGFTRRYV	PDE8A	171	O60658
IVRYLASMRPFAQSF	NIPBL	1756	Q6KC79
SIPSYAFNRVPSLMR	LRRC4	161	Q9HBW1
FMYRTILPGFQRTVA	DSE	296	Q9UL01
RPIDYSSRMLFVFAT	KNTC1	1856	P50748
RMPRYCLFGNTVNLT	GUCY1B1	536	Q02153
AMLFPAPAARRTLTY	PGAP4	336	Q9BRR3
GTLIFMYLRRPTEES	OR5M3	251	Q8NGP4
EMLLSRLSRYRASPS	HECTD4	81	Q9Y4D8
YSRRALINLSPPSMV	IKZF5	191	Q9H5V7
MAPSRLQLGLRAAYS	SLC48A1	1	Q6P1K1
ARLSLRQTGSPGMIY	KCNAB2	11	Q13303
MSRYLLPLSALGTVA	RDH13	1	Q8NBN7
RGLGMTLSYLFREPA	NDUFS8	66	O00217
ILPYDFSRVRLVSMN	PTPRO	971	Q16827
VRADTRLQTPMYFFL	OR6S1	51	Q8NH40
YRMLRSFRPLLFQAS	COG5	726	Q9UP83
YSAVRMARLLSPGAR	COMT	121	P21964
PIRSTGEYMFIRFTS	CUBN	2061	O60494
YMSRIDRVLSFPGGS	DYNC2H1	2636	Q8NCM8
SGILSYPFDTVRRRM	SLC25A31	236	Q9H0C2
VFESTRQLPRFSMYA	BBS2	471	Q9BXC9
RQLPRFSMYALTSLD	BBS2	476	Q9BXC9
ARGFAPLLDFMYTSR	BCL6B	86	Q8N143
MRLGRYSFSSPLTRL	FRMPD2B	301	Q6IN97
MRKFRIDPSTGVLYT	FAT3	1506	Q8TDW7
SSMPGLSRAALYSRL	REXO1L1P	356	Q8IX06
MSPLSAARAALRVYA	DHRSX	1	Q8N5I4
MSGLRVAFPDTRKTY	ABHD17C	236	Q6PCB6
SMLLRRAQPTDSGTY	CEACAM19	106	Q7Z692
VYSMPSRNLSLRLEG	ESAM	101	Q96AP7
PASLTQIYGTFNRAM	DYNC1H1	2741	Q14204
FNRAMLRLIPSLRTY	DYNC1H1	2751	Q14204
ARARSNMFFGLTPLY	KMT2A	2621	Q03164
YTIRALSTNIRPMLG	EML5	1306	Q05BV3
RLLGTYVAMSLRPAA	DNAH9	26	Q9NYC9
RPAAARASLLYFIMN	DNAH9	3676	Q9NYC9
RALPRTYMASVYNTR	GPR146	131	Q96CH1
FASMSRSIGLNPLYI	SLC13A5	476	Q86YT5
YVPFLASTAGVRLML	SCNN1B	306	P51168
VSLRFGGPMTRSYRS	MENT	36	Q9BUN1
NGMLRYRIVSQAPST	CDH2	301	P19022
SYTTLRFPEMNIPRT	CD22	761	P20273
YLATLAGNFRMPVLR	DGAT2	191	Q96PD7
TPMLTPFIYSLRNRD	OR1E2	291	P47887
FTLARQGYPRMAFSA	SLC8B1	476	Q6J4K2
PSLQRTMIRYFTSNP	PARL	186	Q9H300
RLLSGNYSFIPDAMT	MSH5	146	O43196
EAGRYPMSALLSRQF	RTN3	301	O95197
ASRYVQKLPMIGRTS	TAF6L	591	Q9Y6J9
GLYQMLPRFSTFISE	TAF6	251	P49848
PASMYGSTGSLLRRV	PSD	36	A5PKW4
RFIGKPDMAYRLISA	SNAP47	316	Q5SQN1
GFRLTMALSVPLLYS	TMEM121B	351	Q9BXQ6
GMLRARYTELSSPFV	SYNE2	4721	Q8WXH0
PSYRFILNDGTMLSA	NCOA1	326	Q15788
YRMLRSLLSAQGVSP	POMGNT1	316	Q8WZA1
RALRYFDLTPSMAGI	NBEAL2	576	Q6ZNJ1
ARRTPVSYQNTMSRG	NCOR1	1481	O75376
QAFGIRLSTMSPRYL	MORC4	26	Q8TE76
YPRFLSTEAISIMRR	PKN2	876	Q16513
LFMYVRPQAIDSRSS	OR6B3	256	Q8NGW1
SARPRDFLYVGVMTA	CHSY3	166	Q70JA7
GQLASYPLALVRTRM	SLC25A25	391	Q6KCM7
MYRPARVTSTSRFLN	TMPRSS11D	1	O60235
MAAIYLSRGFFSREP	ZNF561	1	Q8N587
SLMPYFLLTQAVRTG	PSMD3	356	O43242
PSQMRRSASLAKLGY	SSH2	1251	Q76I76
SSTLFTMDIYTRLRP	SLC5A2	401	P31639
RGIQYFLQRRPSMKT	TRPV1	491	Q8NER1
PYNQRRMSFLGLASG	SCN10A	481	Q9Y5Y9
RYNFSMPSRLISGSN	TBX22	476	Q9Y458
LAMVIAYFSRAGLPS	SPDYE16	186	A6NNV3
LAMVIAYFSRAGLPS	SPDYE18	226	P0DV79
GADRYTMRSPVLFSN	SYCP2	486	Q9BX26
MAFRRRTKSYPLFSQ	TRAM2	1	Q15035
IAPRYASFLMGISRG	SLC17A2	401	O00624
RAAMLRAISQAPYLG	VWA2	591	Q5GFL6
VGRRPFDKMATLLAY	NF1	1531	P21359
RLISYAQLTGRMPAA	VWA5A	496	O00534
YFTGTSPQNLRLMLL	PKHD1L1	3831	Q86WI1
YLRQTETLTSNLRMP	ZBTB20	476	Q9HC78
ASPRYIFTMLSSLAR	TOP2A	801	P11388
AYPRQLFLLTAASPM	VWA5B2	441	Q8N398
VLSARNSRMFGYLSP	nan	31	A8MUA0
VSFPLYLNGRRMNTL	TRAP1	281	Q12931
LSITLGRRGQYVMLS	TTC7A	386	Q9ULT0
LAMVIAYFSRAGLPS	nan	186	A6NJR5
SPFMAYGSASQLLRT	STRADB	136	Q9C0K7
GIPTYAMSNLFSILR	ERVK-19	286	Q9WJR5
MASERYLGITRPFSR	TBXA2R	126	P21731
YLLVSLIPSNSFRQM	USP34	2686	Q70CQ2
TARRVVYSAFLMATP	EFTUD2	811	Q15029
TYGNFSLATMFPRRE	UBXN4	356	Q92575
LASYPLALVRTRMQA	SLC25A24	401	Q6NUK1
ATYPVRLTNPVSRFM	SOCS6	481	O14544
YLTRIRIFSAFEMSP	TMEM236	336	Q5W0B7
PGMTRSNVLFTSRYG	TTLL7	871	Q6ZT98
MLLSQYSPSRRQEVF	NDC1	336	Q9BTX1